Header
 
Login
 

Privatsphäre-Einstellungen

Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen
Zurück

    FIP/AAPS Guidelines for Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms

    Dr. Martin Siewert1, Prof. Dr. Jennifer Dressman2, Cynthia K. Brown3, and Dr. Vinod P. Shah4

    1 Aventis Pharma AG, Frankfurt/Main (Germany)
    2 Johann Wolfgang Goethe University, Frankfurt/Main (Germany)
    3 Eli Lilly and Company, Indianapolis, I N (USA)
    4 Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD (USA)


    In the pharmaceutical industry, dissolution testing is a very important tool in drug development and quality control. Although initially developed for immediate release (IR) solid oral dosage forms and then extended to controlled/modified release solid oral dosage forms, in recent years the application of dissolution testing has widened to a variety of “novel” or “special” dosage forms. The in vitro drug release test for some novel/special dosage forms such as semi-solid dosage forms and transdermal drug delivery systems has proven to be equally valuable as the dissolution test for solid oral dosage forms. The in vitro drug release test also shows promise for other dosage forms, such as chewable tablets, suspensions and suppositories. For yet other dosage forms, such as chewing gums, powders, and parenterals, further method development and refinement will be needed to make the drug release test a generally applicable, robust and valuable tool.This article represents the scientific opinion of many experts and, in particular, is derived from a series of workshops held under the auspices of FIP co-sponsored by the Royal Pharmaceutical Society (UK), BPI Colloqium Pharmaceuticum (Germany), AAPS American Association of Pharmaceutical Scientists (US) and the Food and Drug Administration (US). It is now presented as an FIP and AAPS position paper to support activities, programs and decisions in the scientific, technical and regulatory community.

     




    © ECV- Editio Cantor Verlag (Germany) 2003

     

    pharmind 2003, Nr. 2, Seite 129